Add Yahoo as a preferred source to see more of our stories on Google. BioInvent's monoclonal antibody has demonstrated an ORR of 24% when combined with MSD's Keytruda during a Phase IIa study in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback